MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine"

  • 2023 International Congress

    The comparison of curcumin and naringenin effects on motor function in rotenone model of Parkinson’s disease

    S. Madiha (Karachi, Pakistan)

    Objective: The aim of the study was to compare the effects of curcumin and naringenin on rotenone-induced motor deficits and related neurochemical changes. Background: Experimental…
  • 2023 International Congress

    Quantitative investigation of the pathway between dopamine receptors and Ca2+ channels in layer II stellate cells towards Parkinson’s disease

    C. Mahapatra, A. Pradhan (MUMBAI, India)

    Objective: Recent experimental data suggest a putative coupling between dopamine D2 receptors (D2R) and T-type Ca2+ channels as another biophysical explanation for the firing pattern…
  • 2023 International Congress

    Tramadol Induces Neuroinflammation, Mitochondrial Oxidative Stress, Neurotransmitters Dysbalanced and Produced Parkinson’s Disease Like Symptoms in Experimental Wistar Rats

    KHA. Aran (Moga, India)

    Objective: The current study is designed to evaluate the possible neurotoxic effects of tramadol in Wistar rats. Background: Parkinson’s disease (PD) is a chronic neurodegenerative…
  • 2022 International Congress

    EFFECTS OF DOPAMINERGIC MEDICATION ON REACTIVE AND PROACTIVE INHIBITORY CONTROL

    G. Mirabella, C. Mancini, O. Olivola, A. Rizzardi, V. Di Caprio, E. Ferrari, N. Modugno, A. Pilotto, A. Padovani (Brescia, Italy)

    Objective: In this study, we aim to address the effects of dopaminergic treatment (DT) on the two domains of motor inhibition [1], i.e., reactive (the…
  • 2022 International Congress

    Remission of Gilles de la Tourette Syndrome Following Dehydration

    A. Durbin, M. Rodgers, J. Brasic, D. Wong (Baltimore, USA)

    Objective: To assess the beneficial and adverse effects of heat on a man with Gilles de la Tourette Syndrome (TS) Background: The effect of heat…
  • 2022 International Congress

    Dopaminergic Denervation as Predictors of Falls in PD Patients

    J. Li, N. Phielipp (Irvine, USA)

    Objective: We aimed to predict fall risk in PD patients using SBR data obtained from PPMI. Background: While dopamine is currently considered to be the…
  • 2022 International Congress

    Continuous circadian intracerebroventricular administration of anaerobically preserved dopamine greatly reduces severe L-dopa-related complications in Parkinson’s disease

    C. Moreau, P. Odou, A. Demailly, G. Touzet, N. Reyns, N. Carta, C. Barthelemy, D. Lannoy, B. Palas, B. Gouges, JC. Devedjian, L. Defebvre, M. Fisichella, D. Devos (Lille, France)

    Objective: We aim to demonstrate the safety and efficacy of continuous circadian intracerebroventricular (i.c.v.) administration of anaerobic-dopamine (A-dopamine) to reduce the L-dopa-related complications (LDRC) in…
  • 2022 International Congress

    The agreement between automated and expert FOG annotations during an at-home protocol: influence of dopaminergic medication and task

    N. D'Cruz, D. Zoetewei, T. Herman, P. Ginis, J. Hausdorff, A. Nieuwboer (Leuven, Belgium)

    Objective: To investigate agreement between a recent automated FOG detection algorithm and expert video ratings, and the influence of dopaminergic medication and task context. Background:…
  • 2022 International Congress

    Gray matter volume of proposed brain-first and body-first Parkinson’s disease subtypes

    M. Banwinkler, V. Dzialas, M. Hoenig, T. van Eimeren (Cologne, Germany)

    Objective: The aim of this study was to test if markers of the brain-first Parkinson’s disease (PD) subtype are associated with a greater or more…
  • 2022 International Congress

    Therapeutic potential of luteolin in manganese induced Parkinson’s disease: Targeting neuroinflammation and oxidative stress.

    S. Chib (Moga, India)

    Objective: To investigate the neurodegenerative facets of Manganese (Mn) in rat model in rat model of Parkinson's disease.To study the neuroprotective effect of luteolin in…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 26
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley